• Disrupting CB1 Signaling: AM 281 for Cognitive Rescue in TBI

  2026-06-01

  This thought-leadership article explores the mechanistic and translational promise of AM 281, a selective CB1 cannabinoid receptor antagonist, in neuropharmacology research. Integrating new evidence on the CB1-CREB-GLT-1 axis and competitive research practices, the piece offers actionable guidance for researchers targeting cognitive dysfunction, with special focus on traumatic brain injury (TBI) models. The article distinguishes itself by bridging mechanistic insights with workflow strategy and protocol realism, moving beyond standard product pages.

• Alda 1: ALDH2 Activator Unlocks New Frontiers in Cardiac Res

  2026-06-01

  Alda 1, a potent ALDH2 activator from APExBIO, is transforming experimental workflows in cardiac ischemia and aldehyde detoxification research. This article reveals validated protocol enhancements, cross-study insights, and troubleshooting strategies that enable reproducible advances in cardioprotection and radiation dermatitis mitigation.

• (-)-Epigallocatechin Gallate (EGCG): Breakthroughs in Bone R

  2026-05-31

  Explore the multifaceted roles of (-)-Epigallocatechin gallate (EGCG) in bone regeneration, advanced scaffold delivery, and cancer chemoprevention. This in-depth article reveals unique assay insights and practical protocols for leveraging EGCG’s bioactivity in translational research.

• Calcitriol in Decidualization and Immune Modulation Workflow

  2026-05-30

  Calcitriol (1,25-dihydroxy vitamin D3) is redefining endometrial decidualization and cytokine inhibition research with precision and reproducibility. Explore advanced protocols, troubleshooting insights, and the latest innovations that position APExBIO Calcitriol as a gold-standard reagent for vitamin D receptor signaling studies.

• Alternariol-Induced Hepatic Stellate Cell Activation in Fibr

  2026-05-29

  This study provides the first multi-omics mechanistic evidence that Alternariol (AOH) and related Alternaria toxins drive hepatic stellate cell (HSC) transdifferentiation into myofibroblasts, implicating these foodborne mycotoxins as direct contributors to liver fibrosis. The findings advance mycotoxin research by highlighting core molecular pathways and presenting a laccase-based detoxification strategy with practical implications for food safety and toxicology.

• Aclacinomycin A: Reliable Benchmark for DNA Damage & Apoptos

  2026-05-29

  Aclacinomycin A (SKU A2601) serves as a validated dual topoisomerase inhibitor and apoptosis inducer, providing quantitative, reproducible results in assays for DNA damage and cell viability. This article addresses practical laboratory scenarios and demonstrates how Aclacinomycin A from APExBIO enables precise experimental outcomes across cell biology and oncology research.

• AM 281: CB1 Cannabinoid Receptor Antagonist in TBI Models

  2026-05-28

  AM 281 stands out as a potent, selective CB1 cannabinoid receptor antagonist, essential for dissecting neuroprotective signaling in traumatic brain injury and cognitive dysfunction models. This guide delivers actionable workflows, technical troubleshooting, and evidence-based strategies to maximize your research impact using AM 281 from APExBIO.

• Biotin-16-UTP: Precision RNA Labeling for Detection & Purifi

  2026-05-28

  Biotin-16-UTP empowers researchers with site-specific RNA labeling, enhancing detection, purification, and RNA-protein interaction studies. Discover how this APExBIO reagent streamlines lncRNA workflows and enables advanced molecular biology applications.

• Cy5.5 NHS Ester: Optimizing In Vivo Fluorescence Imaging Wor

  2026-05-27

  Cy5.5 NHS ester (non-sulfonated) empowers sensitive, covalent labeling of biomolecules for high-definition near-infrared imaging—including deep-tissue optical tumor mapping and biomolecule tracing. This article delivers practical protocols, experimental troubleshooting, and strategic insights for maximizing performance in advanced in vivo fluorescence workflows.

• SP1/ADAM10/DRP1 Axis Regulates SMC–EC Crosstalk in Hypoxic P

  2026-05-27

  Li et al. elucidate a mechanistic axis involving SP1, ADAM10, and DRP1 that governs the communication between endothelial and smooth muscle cells in hypoxia-induced pulmonary hypertension. Their findings clarify how ADAM10-driven signaling promotes smooth muscle cell proliferation and survival via mitochondrial dynamics, suggesting new molecular targets for intervention.

• SIRT1/2 Inhibitor IV: Unlocking Astrocyte Polarization Pathw

  2026-05-26

  Explore how SIRT1/2 Inhibitor IV (cambinol) empowers translational researchers to dissect SIRT1/2-regulated mechanisms underlying astrocyte polarization and tumor biology. This thought-leadership article bridges recent mechanistic breakthroughs in non-histone lactylation with actionable protocol guidance, competitive insights, and forward-looking perspectives for CNS and cancer research.

• Cell Integrity Sets Ploidy Limits in Budding Yeast: Mechanis

  2026-05-26

  The referenced study demonstrates that cell surface integrity fundamentally restricts the maximum ploidy attainable in budding yeast, with physical and genetic factors modulating this upper limit. These findings clarify how cell membrane stress and ergosterol biosynthesis interact with genome doubling, offering new perspectives for antifungal research and the study of polyploidy.

• Gramine Induces Ferroptosis via CUL3–MTDH Axis in TNBC Model

  2026-05-25

  This study elucidates the mechanistic action of Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) as a selective ferroptosis inducer in triple-negative breast cancer (TNBC) by targeting the CUL3–MTDH ubiquitination axis. The findings provide a robust framework for leveraging Gramine in cancer biology research, offering new therapeutic avenues for TNBC models.

• Selective Nanomolar IRAP Inhibitors via α-Hydroxy-β-Amino Ac

  2026-05-25

  This study introduces a highly selective class of insulin-regulated aminopeptidase (IRAP) inhibitors based on α-hydroxy-β-amino acid derivatives of bestatin. The work demonstrates a new synthetic approach with high diastereo- and regioselectivity, validated by structural analysis, and paves the way for future development of potent, cell-active IRAP inhibitors.

• BV6: Unlocking IAP Antagonism for Precision Cancer and Endom

  2026-05-24

  Explore how the IAP antagonist BV6 enables advanced apoptosis induction in cancer and endometriosis studies. This article delves into mechanistic insights, practical protocols, and new perspectives on radiosensitization and therapeutic research, distinguishing itself from standard assay guides.

14586 records 1/973 page Next 12345 下5页 Last page